apoC-III Inhibitors
The apoC-III inhibitors represent a diverse array of chemical compounds that exert inhibitory effects on the expression and function of apolipoprotein C-III (apoC-III), a key regulator of lipid metabolism. Gemfibrozil, a fibric acid derivative, indirectly inhibits apoC-III expression through activation of peroxisome proliferator-activated receptor-alpha (PPAR-α), leading to decreased apoC-III transcription. This highlights the intricate interplay between pharmacological modulation of lipid metabolism and the regulation of apoC-III levels. Apolipoprotein A-I mimetic peptides function as inhibitors by disrupting apoC-III's interaction with lipoproteins, preventing its inhibitory effects on lipoprotein lipase (LPL). This represents a targeted pharmacological approach to counteract the adverse metabolic effects associated with elevated apoC-III levels. Icosabutate, a novel fatty acid derivative, selectively inhibits apoC-III by disrupting its interaction with lipoproteins, reducing its inhibitory influence on LPL. This targeted approach holds promise for mitigating the adverse metabolic effects associated with elevated apoC-III levels. Niacin (nicotinic acid) indirectly inhibits apoC-III expression through activation of G protein-coupled receptor 109A (GPR109A), highlighting the role of signaling pathways in modulating apoC-III transcription.
MicroRNA-122 (miR-122) mimics represent a direct approach to inhibit apoC-III expression by targeting its mRNA, providing a means to enhance endogenous regulatory mechanisms. Statins, exemplified by atorvastatin, indirectly inhibit apoC-III expression through their cholesterol-lowering effects and modulation of the mevalonate pathway. The pleiotropic effects of statins contribute to their potential in reducing apoC-III levels and mitigating cardiovascular risk. Insulin, a key regulator of glucose and lipid metabolism, indirectly inhibits apoC-III expression through its effects on transcription factors such as sterol regulatory element-binding proteins (SREBPs). The pleiotropic effects of resveratrol on cellular pathways contribute to its potential in modulating apoC-III levels and influencing lipid homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil is a fibric acid derivative that indirectly inhibits apoC-III expression. It acts through the peroxisome proliferator-activated receptor-alpha (PPAR-α) pathway, leading to decreased apoC-III transcription. Gemfibrozil is known for its lipid-lowering effects and its role in modulating lipid metabolism, including the regulation of apoC-III. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $62.00 $124.00 | 1 | |
Niacin, also known as nicotinic acid, indirectly inhibits apoC-III expression through activation of G protein-coupled receptor 109A (GPR109A). Niacin-mediated activation of GPR109A leads to downstream effects, including the inhibition of cAMP signaling and subsequent reduction in apoC-III transcription. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin, a statin class agent in research, indirectly inhibits apoC-III expression through its cholesterol-lowering effects. Statins act on the mevalonate pathway, leading to downstream effects that influence transcription factors involved in lipid metabolism, including apoC-III. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin indirectly inhibits apoC-III expression through its regulatory effects on transcription factors. Insulin promotes the activation of sterol regulatory element-binding proteins (SREBPs), which play a role in lipid metabolism and can influence apoC-III transcription. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol is a natural polyphenol that indirectly inhibits apoC-III expression through its impact on sirtuin 1 (SIRT1) activity. Resveratrol activates SIRT1, which can deacetylate and inhibit SREBP-1, a transcription factor involved in lipid metabolism, including apoC-III transcription. | ||||||